Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Venus Medtech (Hangzhou)HKSE:02500 -3.64%52 Gross Margin % is 61.72% as of Dec. 2025, which is 22% below its 10-year median of 79.21. GuruFocus rates HKSE:02500 with a GF Score™ of 52/100 and a GF Value™ of HK$3.35 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 806 Medical Devices & Instruments companies, Venus Medtech (Hangzhou) ranks better than 78.04% on this metric.
HKSE:02500's Gross Margin % is ranked better than 78.04% of 806
companies
in the Medical Devices & Instruments industry
Industry Median: 52.115
vs HKSE:02500: 69.02
Venus Medtech (Hangzhou) had a gross margin of 61.72% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Venus Medtech (Hangzhou) was -2.40% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Venus Medtech (Hangzhou) had a gross margin of 61.72% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Venus Medtech (Hangzhou) Gross Margin % Related Terms
Venus Medtech (Hangzhou) Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02500 vs ABT, SYK, MDT: Gross Margin % Comparison
For the Medical Devices subindustry, Venus Medtech (Hangzhou)'s Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Venus Medtech (Hangzhou) Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Venus Medtech (Hangzhou)'s Gross Margin % distribution charts can be found below:
* The bar in red indicates where Venus Medtech (Hangzhou)'s Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Venus Medtech (Hangzhou) (HKSE:02500) has a Gross Margin % of 61.72% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Venus Medtech (Hangzhou) and its competitors. This is 22% below median its historical median of 79.21. Over the past decade, Venus Medtech (Hangzhou)'s Gross Margin % has ranged from 69.02 to 85.81. According to the industry distribution chart, Venus Medtech (Hangzhou) ranks #177 out of 806 companies in the Medical Devices & Instruments industry, placing it in the top 22%.
Is Venus Medtech (Hangzhou)'s Gross Margin % too high?
Venus Medtech (Hangzhou)'s current Gross Margin % of 61.72% is 22% below median its 10-year median of 79.21. Over the past 10 years, this metric has ranged from a low of 69.02 to a high of 85.81. The Medical Devices & Instruments industry median Gross Margin % is 52.12. Venus Medtech (Hangzhou)'s value of 61.72% is 18.4% above this industry median. Based on the distribution chart, Venus Medtech (Hangzhou) ranks #177 out of 806 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Venus Medtech (Hangzhou) has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Venus Medtech (Hangzhou)'s Gross Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Venus Medtech (Hangzhou) ranks #177 out of 806 companies for Gross Margin %. This places Venus Medtech (Hangzhou) in the top 22% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 52.12. Venus Medtech (Hangzhou)'s value of 61.72% is 18.4% above this benchmark. Historically, Venus Medtech (Hangzhou)'s own Gross Margin % has ranged from 69.02 to 85.81 over the past decade. While the company's 10-year median is 79.21 vs. the industry median of 52.12, Venus Medtech (Hangzhou) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 52.12, based on 806 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Venus Medtech (Hangzhou)'s current Gross Margin % of 61.72% is 18.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Venus Medtech (Hangzhou) and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 52.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Venus Medtech (Hangzhou)'s current Gross Margin % is 61.72%, which is 22% below median its own 10-year median of 79.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venus Medtech (Hangzhou) stock overvalued right now?
Based on GuruFocus' analysis, Venus Medtech (Hangzhou) (HKSE:02500) is currently considered Possible Value Trap. The stock's GF Value™ is HK$3.35, compared to a current price of HK$1.06 — trading 68.4% below its estimated fair value. The current Gross Margin % is 61.72%, which is 22% below median its 10-year median of 79.21 and 18.4% above the Medical Devices & Instruments industry median of 52.12. Venus Medtech (Hangzhou)'s overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Venus Medtech (Hangzhou) (HKSE:02500), the current Gross Margin % is 61.72% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Venus Medtech (Hangzhou) (HKSE:02500) Overvalued in 2026?
Based on GuruFocus' analysis, Venus Medtech (Hangzhou) stock appears to be undervalued.
The current stock price of HK$1.06 is trading 68.4% below its estimated GF Value™ of HK$3.35.
GuruFocus considers Venus Medtech (Hangzhou) to be Possible Value Trap.
Key valuation signals for HKSE:02500:
Gross Margin %: 61.72% (22% below median its 10-year median of 79.21)
GF Value™: HK$3.35 vs. price of HK$1.06 (68.4% below fair value)
Industry Position: 18.4% above the Medical Devices & Instruments median (#177 of 806)
No single metric tells the full story. See the HKSE:02500 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Venus Medtech (Hangzhou) Inc is engaged in the medical devices that integrate R&D, clinical development, manufacturing, and commercialization. The company has developed a product portfolio covering the interventional devices for valvular heart diseases, including transcatheter aortic valve replacement (TAVR), transcatheter pulmonary valve replacement (TPVR), transcatheter mitral valve replacement (TMVR), transcatheter tricuspid valve replacement (TTVR), and other procedural accessories, allowing it to provide overall solutions for physicians and patients. Geographically, the company operates in mainland China, Israel, Hong Kong, the USA, and the Netherlands. The majority of the revenue is derived from Mainland China.
52GF Score
Get the complete analysis for HKSE:02500
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02500 has been successfully added to your 
